Latest news with #Janssen
Globe and Mail
6 days ago
- Business
- Globe and Mail
CAR T-Cell Therapy for Multiple Myeloma Pipeline Experiences Rapid Expansion as Over 5+ Leading Companies Advance Novel Therapies
DelveInsight's, 'CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2025,' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the CAR T-Cell Therapy for Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy for Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Dive into DelveInsight's comprehensive report today! @ CAR T-Cell Therapy for Multiple Myeloma Pipeline Outlook Key Takeaways from the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report In July 2025, Janssen Research & Development LLC announced a study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS). DelveInsight's CAR T-Cell Therapy for Multiple Myeloma pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for CAR T-Cell Therapy for Multiple Myeloma treatment. The leading CAR T-Cell Therapy for Multiple Myeloma Companies such as Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. Promising CART-Cell Therapy for Multiple Myeloma Pipeline Therapies such as Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. Stay ahead with the most recent pipeline outlook for CAR T-Cell Therapy for Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ CAR T-Cell Therapy for Multiple Myeloma Treatment Drugs CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Profile Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the multiple myeloma treatment. JNJ-68284528: Janssen Biotech Janssen's drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status. The CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy for Multiple Myeloma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Multiple Myeloma Treatment. CAR T-Cell Therapy for Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. CAR T-Cell Therapy for Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy for Multiple Myeloma market Explore groundbreaking therapies and clinical trials in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New CAR T-Cell Therapy for Multiple Myeloma Drugs CAR T-Cell Therapy for Multiple Myeloma Companies Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Molecule Type CAR T-Cell Therapy for Multiple Myeloma Products have been categorized under various Molecule types such as Small molecules Natural metabolites Monoclonal antibodies Product Type Unveil the future of CAR T-Cell Therapy for Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ CAR T-Cell Therapy for Multiple Myeloma Market Drivers and Barriers Scope of the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Coverage- Global CAR T-Cell Therapy for Multiple Myeloma Companies- Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CART-Cell Therapy for Multiple Myeloma Pipeline Therapies- Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on CAR T-Cell Therapy for Multiple Myeloma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ CAR T-Cell Therapy for Multiple Myeloma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary CAR T-Cell Therapy for Multiple Myeloma: Overview Pipeline Therapeutics Therapeutic Assessment CAR T-Cell Therapy for Multiple Myeloma – DelveInsight's Analytical Perspective In-depth Commercial Assessment CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals Early Stage Products (Phase I) PHE 885: Novartis Drug profiles in the detailed report….. Pre-clinical Stage JNJ-68284528: Janssen Biotech Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products Drug profiles in the detailed report….. Inactive Products CAR T-Cell Therapy for Multiple Myeloma Key Companies CAR T-Cell Therapy for Multiple Myeloma Key Products CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion CAR T-Cell Therapy for Multiple Myeloma Analyst Views CAR T-Cell Therapy for Multiple Myeloma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Medical News Today
09-07-2025
- Health
- Medical News Today
Foods to avoid while receiving Stelara
Stelara has no known food interactions, but diet is still an important part of symptom management for the conditions the drug is a brand-name drug that doctors prescribe to treat certain autoimmune conditions, including:plaque psoriasis in certain adults and children ages 6 years and olderpsoriatic arthritis in adults and children ages 6 years and olderCrohn's disease in adultsulcerative colitis in adultsWhile Stelara doesn't interact with any foods, certain foods may affect the conditions Stelara treats or help with the drug's side effects.»Learn more about Stelara, including it's uses and to avoid while receiving StelaraThere are no reports of Stelara interacting with certain foods and beverages can increase inflammation in your body. This can trigger symptoms of the conditions you're receiving Stelara to treat. Examples of these foods and beverages include:Processed foods: Processed foods, such as prepackaged snacks or meals, link to a higher risk of autoimmune foods: A 2023 research review showed a link between sugar consumption and psoriasis flare-ups. A diet high in sugary foods, such as candy, cookies, cake, and drinks, is likely to worsen symptoms of conditions caused by or fatty foods: Foods high in saturated and trans fat, such as fried foods, processed snacks, and fatty meats, can also increase While there's no interaction between alcohol and Stelara, alcohol may worsen symptoms of the condition you're receiving Stelara to treat.»Learn more about drugs and vaccines that interact with tips for managing the side effects of StelaraSome common side effects reported in Stelara's studies include:nauseavomitingabdominal paindiarrheaAvoiding or eating certain foods may help with managing these side example, if you're experiencing diarrhea, eating foods high in soluble fiber, such as bananas, oatmeal, and rice, may be helpful to thicken the stool. On the other hand, it may be best to limit creamy, fried, high dairy, and sugary foods, as these can worsen you're experiencing vomiting while receiving Stelara, eating smaller meals throughout the day, instead of three large meals, may be helpful. You also may want to avoid spicy hydrated is also important to help manage these digestive side you have questions about managing Stelara's side effects, talk with your doctor or pharmacist.»Learn more about side effects of Stelara doesn't interact with food, certain foods, including sugary foods, may increase the risk of symptoms of the condition you're receiving the drug to may also need to avoid or eat certain foods to help manage the digestive side effects of with your doctor or pharmacist if you have questions about foods and Stelara.
Otago Daily Times
06-07-2025
- Sport
- Otago Daily Times
Nuggets break losing streak with final win against Jets
Jonathan Janssen of the Otago Nuggets was big all game against the Manawatu Jets in Palmerston North this afternoon. File photo: Gregor Richardson There is something to be said for how you finish. The Otago Nuggets wrapped up their NBL season with a 101-95 win against the Manawatu Jets in Palmerston North this afternoon. There were plenty of happy faces in the Nuggets camp after they snapped a 15 game losing streak. Coincidentally their last win came against the Jets, when they scored a 108-104 victory on March 27. It brought an end to the Jets' season, who will now finish outside of the playoff spot they were hunting. Jonathan Janssen was big all game, finishing with 25 points, six rebounds, three assists and one block. Import Jaylen Seebree recorded a double of 16 points, 12 rebounds, and had eight assists and one block. Matthew Bardsley was busy with 14 points and Mac Stodart banked 15 from the bench. Janssen stood up in the opening quarter with 12 points, including two from deep. Seebree banked two from the free throw line to give the Nuggets a 29-28 lead at the first break. Veteran Leon Henry controlled the Jets early in the second. The 39-year-old banked two from beyond the arc and Tyson Thata added another to regain the lead. Janssen used the ball to shift the Jets' defence, giving the ball to Darcy Knox in the corner to drain a three. The Jets came back late in the quarter to trail 52-51 at halftime. The home side came out of the break and put their foot down. They went on an 11-4 run to take an eight-point lead. The Nuggets pulled it back and won the quarter 25-20 to lead 77-71 at the break. The Nuggets won their final Rapid League clash 37-23.
Otago Daily Times
06-07-2025
- Sport
- Otago Daily Times
Nuggets snap losing streak with final win against Jets
Jonathan Janssen of the Otago Nuggets was big all game against the Manawatu Jets in Palmerston North this afternoon. File photo: Gregor Richardson There is something to be said for how you finish. The Otago Nuggets wrapped up their NBL season with a 101-95 win against the Manawatu Jets in Palmerston North this afternoon. There were plenty of happy faces in the Nuggets camp after they snapped a 15 game losing streak. Coincidentally their last win came against the Jets, when they scored a 108-104 victory on March 27. It brought an end to the Jets' season, who will now finish outside of the playoff spot they were hunting. Jonathan Janssen was big all game, finishing with 25 points, six rebounds, three assists and one block. Import Jaylen Seebree recorded a double of 16 points, 12 rebounds, and had eight assists and one block. Matthew Bardsley was busy with 14 points and Mac Stodart banked 15 from the bench. Janssen stood up in the opening quarter with 12 points, including two from deep. Seebree banked two from the free throw line to give the Nuggets a 29-28 lead at the first break. Veteran Leon Henry controlled the Jets early in the second. The 39-year-old banked two from beyond the arc and Tyson Thata added another to regain the lead. Janssen used the ball to shift the Jets' defence, giving the ball to Darcy Knox in the corner to drain a three. The Jets came back late in the quarter to trail 52-51 at halftime. The home side came out of the break and put their foot down. They went on an 11-4 run to take an eight-point lead. The Nuggets pulled it back and won the quarter 25-20 to lead 77-71 at the break. The Nuggets won their final Rapid League clash 37-23.
Otago Daily Times
04-07-2025
- Sport
- Otago Daily Times
Nuggets lead at every break until Airs finally take control
Jonathan Janssen. PHOTO: GREGOR RICHARDSON The Otago Nuggets lost 93-83 to the Taranaki Airs in New Plymouth last night. The Nuggets led at every break — by as much as 11 — until the Airs took a 65-64 lead early in the fourth quarter. A scuffle erupted between Jack Exeter and Josh Aitcheson, leading to both players being ejected. Craig Moller came up with some big shots for the Airs late to lead 87-82 and they powered home from there. It was another frustrating end for the Nuggets, who kept the third-placed Airs quiet through the opening half. Jonathan Janssen stepped up for the Nuggets without import Don Carey jun. The centre finished with a double of 19 points and 11 rebounds and Jaylen Seebree scored 24 points. Carlin Davison finished with 25 points and 10 rebounds for the Airs. The Nuggets had a strong start. But Davison found his way through to finish off and the Airs trailed 16-15. He then fired in back-to-back balls that former Nugget Jack Andrew finished off at the hoop. Christian Martin then banged down consecutive triples to keep the Nuggets in front 26-21 at the break. The Nuggets cleaned up the Airs' turnovers and suddenly held a 32-23 lead. Davison still managed to weave through and was aggressive to the hoop. Dominique Kelman-Polo came into the game for the Airs. He used his size in the paint. Janssen finished off from down low to reinstate a nine-point lead for the Nuggets. Missed free throws hurt the Airs, but Deng Dut nailed a triple for the Airs trailed 48-44 at halftime. Janssen attacked the bucket to help the Nuggets to an 11-point lead. The big man was prolific for the Nuggets in the paint. Scott Telfer held his ground as Caleb Smiler came steaming into the hoop and was called for the charging foul. Janssen then coughed up a charging foul and Sebree was called for travelling as the momentum began to change. They closed it to 61-58 when Mac Stodart shrugged off his defender to drain a triple for the Nuggets to lead 64-62 at the break. The Nuggets won the Rapid League game 51-49. They meet the Manawatu Jets tomorrow. NBL The scores Taranaki Airs 93 Carlin Davison 25, Craig Moller 24, Otago Nuggets 83 Jaylen Seebree 24, Jonathan Janssen 19 Quarter scores: Nuggets 26-21, 48-44, 64-62.
